1

2
Cwirla Steven E, Balu Palani, Duffin David J, Piplani Sunila, Mceowen Merrill Barbara, Schatz Peter J: Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr). Glaxo Group, Cwirla Steven E, Balu Palani, Duffin David J, Piplani Sunila, Mceowen Merrill Barbara, Schatz Peter J, REED Dianne E, January 31, 2002: WO/2002/007676

Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the ...


3

4
Balu Palani: (epo) Receptor, and associated methods of synthesis and use. Glaxo Group, Balu Palani, STRACKER Elaine C, May 31, 2001: WO/2001/038342

Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain R?1¿ and a second peptide chain R?2¿, wherein R?1¿ and R?2¿ may be the same or different, and are linked through a linking m ...


5
Schatz Peter Joseph, Chen Min Jia, Piplani Sunila, Mozsgai Cecilia A, Balu Palani: Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses. Glaxo Group, Schatz Peter Joseph, Chen Min Jia, Piplani Sunila, Mozsgai Cecilia A, Balu Palani, NORTON Vicki G, November 8, 2001: WO/2001/083693

Novel compounds are provided that bind to VEGFR-2. The novel compounds have a peptide chain approximately 8 to 40 amino acids in length that binds to VEGFR-2, or are dimers of such peptide chains. The compounds are useful as probes for affinity screening and as angiogenesis imaging agents. In additi ...


6
Xu Caiding, Yang Lydie, Bhandari Ashok, Holmes Chris, Chen Min Jia, Schatz Peter, Balu Palani: Peptides and compounds that bind to the il-5 receptor. Affymax, Xu Caiding, Yang Lydie, Bhandari Ashok, Holmes Chris, Chen Min Jia, Schatz Peter, Balu Palani, KREUSSER Edward O, February 16, 2006: WO/2006/017343

New IL-5 receptor antagonists and methods of use are described, e.g., in the treatment of IL-5 receptor mediated disorders. The compounds include both monomers and dimers that were identified using one or more of alanine scans, lysine scans, other residue substitutions, and C- and N-terminal truncat ...